To the Editor We read with interest the Viewpoint by Morrow and Winer considering the need for surgery in diagnoses ranging from ductal carcinoma in situ (DCIS) to postneoadjuvant invasive breast cancer.1 These are 2 very different clinical situations, so here we consider in more detail the situation for DCIS. Arguing against active surveillance, Morrow and Winer cite the risk of missing invasive cancer, the need for more intensive follow-up, more biopsies, and patient anxiety. These are all arguments that over the years have been deployed against the concept of active surveillance for thyroid cancer, prostate cancer, and renal carcinoma for which, based predominantly on evidence from prospective trials, active surveillance is now an accepted management option.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hwang ES, Thompson AM, Wesseling J. De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. JAMA Oncol. 2020;6(7):1117–1118. doi:10.1001/jamaoncol.2020.0816
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: